Abstract

Measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels has been shown to have clinical significance for diagnosis and management of heart disease in dogs. Evaluation of current reference limits for specific breeds is necessary to ensure the test can accurately distinguish between healthy and diseased animals. The objective of this study is to evaluate the adequacy of currently established NT-proBNP reference limits for clinical use in healthy Salukis. Cardiac health of 33 clinically healthy Salukis was evaluated via echocardiography using available breed standards. Plasma concentrations of NT-proBNP were measured using a commercially available assay. A one-sided 97.5% upper reference limit for the NT-proBNP concentrations was calculated using non-parametric percentile method. The 97.5% upper reference limit was 769 pmol/L (90% CI, 547-1214 pmol/L) for the study dogs. This upper reference limit was within the currently established non-breed specific NT-proBNP upper reference limit of 900 pmol/L. No relationship between sex, age, or body weight on plasma levels of NT-proBNP was noted. Results of this study supports the use of currently available non-breed specific NT-proBNP cut-off values for clinical evaluation of healthy Salukis.

Highlights

  • Initial evaluation of cardiac disease in veterinary patients has traditionally lacked a readily accessible and objective method of quantitative evaluation

  • Evaluation of natriuretic peptide levels has been widely used for quantitative assessment of various cardiac diseases

  • Natriuretic peptides have been used in the management of structural heart diseases, acute coronary syndromes, and atrial fibrillation in human patients [1,2,3]

Read more

Summary

Introduction

Initial evaluation of cardiac disease in veterinary patients has traditionally lacked a readily accessible and objective method of quantitative evaluation. Methods such as, electrocardiography, thoracic radiography and echocardiography can be inaccessible to clinicians and owners alike. Evaluation of natriuretic peptide levels has been widely used for quantitative assessment of various cardiac diseases. In human patients with heart failure, natriuretic peptides have utility as a diagnostic tool but can be used to develop prognoses and inform treatment strategies [1, 2]. Natriuretic peptides have been used in the management of structural heart diseases, acute coronary syndromes, and atrial fibrillation in human patients [1,2,3].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call